Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 5: Patient Safety and Quality Assurance
5PSQ-098
PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES
5PSQ-097
AN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY
5PSQ-096
DESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART
5PSQ-095
HOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA
5PSQ-094
INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE.
5PSQ-093
DOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS?
5PSQ-092
ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION
5PSQ-091
SUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT
5PSQ-090
CAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN
5PSQ-089
OUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-19
5PSQ-088
ADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS
5PSQ-087
ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS
5PSQ-086
ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES
5PSQ-085
SAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE
5PSQ-084
EROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT.
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
Follow Us